Our Pricing

Wegovy vs Mounjaro UK Comparison: Which Weight Loss Injection Works Best?

Choosing between wegovy vs mounjaro uk comparison options can feel overwhelming when both are MHRA-licensed weight loss injections. At Cured Pharmacy, our UK-registered clinical team helps patients understand the key differences in mechanism, efficacy, side effects, and pricing to make an informed choice. Both require prescription assessment by a UK prescriber before dispensing.

How Mounjaro and Wegovy Work Differently

Mounjaro (tirzepatide) is the UK's first dual GIP/GLP-1 receptor agonist, meaning it activates two distinct hormonal pathways that regulate appetite, blood sugar, and energy metabolism [1]. By targeting both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, Mounjaro produces synergistic effects that clinical trials suggest may lead to greater weight reduction compared to single-pathway treatments.

Wegovy (semaglutide) works exclusively through GLP-1 receptor activation, slowing gastric emptying, reducing appetite, and improving glycaemic control [2]. While this single-pathway mechanism has proven highly effective in clinical practice, the dual-action approach of tirzepatide represents a newer generation of weight management therapy. Both medications are administered as once-weekly subcutaneous injections and require gradual dose escalation under UK prescriber supervision.

Clinical Trial Data: Wegovy vs Mounjaro Efficacy

In the landmark SURMOUNT-1 trial, participants taking the highest maintenance dose of Mounjaro (15 mg weekly) achieved an average body weight reduction of 22.5% over 72 weeks [1]. This represents one of the highest efficacy rates observed in obesity pharmacotherapy to date. Patients on lower maintenance doses (10 mg and 5 mg) still demonstrated substantial reductions of 21.1% and 15.0% respectively.

The STEP trials evaluating Wegovy showed that participants on the 2.4 mg weekly maintenance dose achieved an average weight loss of 14.9% over 68 weeks [2]. While lower than tirzepatide's peak results, this still represents clinically significant weight reduction that substantially exceeds lifestyle intervention alone. Both medications demonstrated sustained weight loss when combined with reduced-calorie diet and increased physical activity.

Head-to-head comparison data remains limited, but indirect comparisons suggest tirzepatide may offer superior weight reduction outcomes in some patient populations [3]. However, individual response varies considerably, and factors including tolerability, side effect profile, medical history, and concurrent medications influence which treatment a UK prescriber may recommend for you.

Real-World Effectiveness Beyond Trials

Clinical trial populations undergo rigorous screening and may not fully represent real-world patients with complex medical histories or multiple medications. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) notes that in clinical practice, patient adherence, tolerability, and lifestyle factors significantly influence outcomes. Some patients achieve exceptional results with either medication, while others may experience more modest weight reduction or need to switch treatments due to side effects.

Side Effects: What to Expect from Each Medication

Both Mounjaro and Wegovy share a similar gastrointestinal side effect profile, as both influence gut hormone pathways. The most commonly reported adverse effects include nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [1][2]. These symptoms typically emerge during dose escalation phases and often diminish as your body adapts to the medication over several weeks.

In clinical trials, approximately 44% of Mounjaro participants experienced nausea compared to 44% of Wegovy participants, suggesting comparable tolerability profiles [1][2]. However, the dual-receptor mechanism of tirzepatide may produce slightly different symptom patterns in some individuals. Severe gastrointestinal side effects leading to treatment discontinuation occurred in approximately 6-7% of participants across both medications.

Rarer but serious adverse effects requiring immediate medical attention include pancreatitis symptoms (severe persistent abdominal pain), signs of thyroid tumours (neck lump, hoarseness, difficulty swallowing), severe allergic reactions, and gallbladder problems. Both medications carry a boxed warning regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains uncertain [4]. Your UK prescriber will assess your personal and family medical history before prescribing either treatment.

Managing Side Effects in Clinical Practice

Most patients find gastrointestinal symptoms manageable through dietary adjustments such as smaller portion sizes, avoiding high-fat meals, eating slowly, and staying well-hydrated. If side effects become problematic, your prescriber may adjust your dose escalation schedule or recommend symptomatic management strategies. Never adjust your dose without consulting your UK prescriber, as this may compromise both efficacy and safety.

Dosing Schedules and Administration

Mounjaro follows a structured dose escalation protocol starting at 2.5 mg weekly for four weeks, then increasing to 5 mg weekly [1]. If additional weight reduction is needed and the medication is well-tolerated, your prescriber may increase the dose in 2.5 mg increments at four-week intervals, up to a maximum maintenance dose of 15 mg weekly. This gradual titration minimises gastrointestinal side effects whilst optimising therapeutic response.

Wegovy begins at 0.25 mg weekly for four weeks, doubling to 0.5 mg for weeks 5-8, then progressing through 1 mg and 1.7 mg doses before reaching the 2.4 mg maintenance dose by week 17 [2]. Both medications use pre-filled single-dose pens that patients self-administer subcutaneously into the abdomen, thigh, or upper arm. Injection technique training is provided during your initial consultation, and both pens are designed for ease of use without requiring manual needle attachment.

Consistency matters: inject on the same day each week, though the specific time of day is flexible. If you miss a dose and fewer than five days have passed, take it as soon as you remember. If more than five days have elapsed, skip that dose and resume your regular schedule. Never double doses to compensate for missed injections.

Wegovy vs Mounjaro UK: Pricing and Value Comparison

At Cured Pharmacy, Mounjaro is available from £135.00 per month, whilst Wegovy starts from £135.00 per month (reduced from £135.00). Final pricing depends on your prescribed dose, treatment duration, and any applicable promotions. Unlike some online pharmacies, we display transparent pricing before you begin your consultation, with no hidden fees or subscription traps.

When evaluating value, consider not just the monthly cost but also efficacy data, tolerability, and your individual response. Some patients find the higher upfront cost of Mounjaro justified by potentially greater weight reduction, whilst others achieve excellent results with Wegovy at a lower price point. Both medications represent significant investments in your health, and our UK prescribers can discuss which option offers the best balance of clinical benefit and affordability for your circumstances.

We guarantee the lowest prices in the UK for genuine licensed medications. All prescriptions are dispensed by our GPhC-registered pharmacy (9012511) with 100% discreet packaging and next-day delivery options available. Payment plans and subscription services are available to help manage ongoing treatment costs, with full flexibility to pause or cancel at any time.

Insurance and NHS Availability

Weight loss medications are rarely covered by private health insurance in the UK unless prescribed for specific medical conditions such as type 2 diabetes. NHS availability remains extremely limited due to NICE guidance restrictions and regional formulary decisions. Most UK patients access these treatments through private prescriptions from online pharmacies like Cured Pharmacy, where clinical assessment, prescription, and medication supply are provided as an integrated service.

Choosing Between Mounjaro and Wegovy: Clinical Decision Factors

Your UK prescriber will consider multiple factors when recommending between these medications, including your BMI, weight loss goals, medical history, concurrent medications, previous treatment responses, and budget. Patients with type 2 diabetes may have different considerations than those seeking weight management alone, as both medications improve glycaemic control alongside weight reduction [1][2].

Contraindications and cautions differ slightly between the two treatments. Both are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Neither medication is licensed for use during pregnancy or breastfeeding. Drug interactions require careful review, particularly with medications affecting gastric emptying or those with narrow therapeutic windows.

Some patients begin with one medication and later switch to the other based on tolerability or efficacy. This is a normal part of weight management therapy, as individual responses vary considerably. Our clinical team provides ongoing support throughout your treatment journey, with regular check-ins to monitor progress, manage side effects, and adjust therapy as needed. You're never locked into a single treatment path.

Starting Your Weight Loss Journey at Cured Pharmacy

Begin with our free online consultation, which takes under three minutes to complete. Our UK-registered prescribers review your medical history, current medications, and weight loss goals to determine whether Mounjaro, Wegovy, or an alternative treatment is most appropriate for you. If approved, your medication is dispensed from our GPhC-registered pharmacy and delivered discreetly to your door, typically within 24-48 hours. Ongoing prescriptions include regular clinical reviews to ensure safe, effective treatment tailored to your individual needs.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
2. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
3. Nauck, M. A., D'Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovascular Diabetology, 21(1), 169. https://doi.org/10.1186/s12933-022-01604-7
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. Retrieved from https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on multiple factors including adherence to reduced-calorie diet and increased physical activity. Cured Pharmacy does not guarantee specific treatment outcomes.